Coherus Oncology, Inc.
NASDAQ Global MarketTotal Valuation
Coherus Oncology, Inc. carries a market capitalization of 219.39M, placing it among publicly traded companies globally. Its enterprise value stands at 150.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 219.39M |
| Enterprise Value | 150.61M |
Share Statistics
Coherus Oncology, Inc. currently has 154.47M shares outstanding.
| Shares Outstanding | 154.47M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Coherus Oncology, Inc. trades at a trailing price-to-earnings ratio of 3.33. The price-to-sales ratio is 3.63, and the price-to-book ratio stands at 3.55.
| PE Ratio | 3.33 |
| PS Ratio | 3.63 |
| PB Ratio | 3.55 |
| P/TBV Ratio | 13.64 |
| P/FCF Ratio | -0.99 |
| P/OCF Ratio | -0.99 |
Enterprise Valuation
| EV / Sales | 2.96 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Coherus Oncology, Inc. maintains a current ratio of 1.74, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.18, indicating elevated leverage, while an interest coverage ratio of -17.07 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.74 |
| Quick Ratio | 1.55 |
| Debt / Equity | 65.18 |
| Debt / EBITDA | -0.26 |
| Interest Coverage | -17.07 |
Financial Efficiency
| Return on Equity (ROE) | -146.27 |
| Return on Assets (ROA) | -41.90 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.11 |
Stock Price Statistics
Coherus Oncology, Inc.'s stock has gained approximately 10.07752% over the past 52 weeks. The 50-day moving average sits at 1.41, while the 200-day moving average is 1.57.
| Beta (5Y) | N/A |
| 52-Week Price Change | 10.07752% |
| 50-Day Moving Average | 1.41 |
| 200-Day Moving Average | 1.57 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Coherus Oncology, Inc. generated 50.94M in revenue and converted that into -132.13M in net income, yielding earnings per share of -1.22. EBITDA reached -155.09M, while operating income came in at -158.69M.
| Revenue | 50.94M |
| Gross Profit | 35.11M |
| Operating Income | -158.69M |
| Pretax Income | -161.15M |
| Net Income | -132.13M |
| EBITDA | -155.09M |
| EBIT | -158.69M |
| Earnings Per Share (EPS) | -1.22 |
Balance Sheet
Coherus Oncology, Inc. holds 105.31M in cash and equivalents against 39.65M in total debt, resulting in a net debt position of -45.68M. Total book value stands at 60.84M, with working capital of 56.79M providing operational flexibility.
| Cash & Cash Equivalents | 105.31M |
| Total Debt | 39.65M |
| Net Debt | -45.68M |
| Equity (Book Value) | 60.84M |
| Book Value Per Share | 0.39 |
| Working Capital | 56.79M |
Cash Flow
Coherus Oncology, Inc. produced -186.03M in operating cash flow over the past twelve months.
| Operating Cash Flow | -186.03M |
| Capital Expenditures | N/A |
| Free Cash Flow | -186.03M |
| FCF Per Share | -1.41 |
Margins
Coherus Oncology, Inc. operates with a gross margin of 68.94, reflecting its pricing power and cost economics. The operating margin of -311.56 and net profit margin of -259.41 provide insight into operational efficiency.
| Gross Margin | 68.94 |
| Operating Margin | -311.56 |
| Pretax Margin | -316.37 |
| Profit Margin | -259.41 |
| EBITDA Margin | -304.48 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -28.58 |
| FCF Yield | -100.70 |
Scores
Coherus Oncology, Inc. posts an Altman Z-Score of -15.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -15.58 |